ConductScience.org, home

Comparison · NCT03945019-5be04ca3

CT-P13 SC 120 mg vs Placebo: Percentage of Patients Achieving Clinical Remission (Based on AP and SF) at Week 54

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. CT-P13 SC 120 mg vs Placebo: Percentage of Patients Achieving Clinical Remission (Based on AP and SF) at Week 54. Trial comparisons, record NCT03945019-5be04ca3. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03945019-5be04ca3

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.5670.5030.629wilson
Risk in group 20.3130.2340.403wilson
Risk difference, group 1 minus group 20.2550.1430.355newcombe hybrid score
Risk ratio, group 1 over group 21.811.352.44log
Odds ratio, group 1 over group 22.881.794.64log
Number needed to treat, for one more participant with the outcome on CT-P13 SC 120 mg than on Placebo3.932.826.98from the risk difference interval

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1CT-P13 SC 120 mgCT-P13 SC 120 mg131231OG000
Group 2PlaceboPlacebo35112OG001

Outcome

Type
SECONDARY
Title
Percentage of Patients Achieving Clinical Remission (Based on AP and SF) at Week 54
Description
Clinical remission was defined as an average worst daily Abdominal Pain (AP) score of ≤1 (using 4-point scale) and an average daily loose/watery Stool Frequency (SF) score of ≤3 (of Type 6 or Type 7 on Bristol Stool Form Scale (BSFS)) with no worsening in either average score compared with the baseline value.~AP score is patient recorded score on a scale 0 to 3 (none, mild, moderate, or severe) and higher score indicates severe abdominal pain. SF score is patient recorded number of loose/watery stool defined as BSFS type 6 or 7 per day. BSFS is an ordinal scale of stool types ranging from the hardest (Type 1) to the softest (Type 7).~Patients with dose adjustment to CT-P13 SC 240 mg prior to Week 54 were considered as non-remitter.
Time frame
Week 54
Population
All-randomized population

Source ClinicalTrials.gov

Trial

Title
CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Crohn's Disease (LIBERTY-CD)
NCT number
NCT03945019
Phases
PHASE3
Conditions
Crohn's Disease
Interventions
CT-P13 SC (Infliximab), Placebo SC
Lead sponsor
Celltrion
Results first posted
2023-10-23

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT03945019-5be04ca3